

NASH After Liver Transplantation: Impact of Immunosuppression



Sunil Taneja*, Akash Roy†, Ajay Duseja*

*Department of Hepatology, Postgraduate Institute on Medical Education & Research, Chandigarh, India and †Institute of Gastrosciences and Liver Transplantation Apollo Multispecialty Hospitals, Kolkata, India

Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the common causes of cirrhosis and hepatocellular carcinoma (HCC) and is a leading indication for liver transplantation (LT). Patients with NAFLD-related cirrhosis and HCC are at high risk for the development of recurrent NAFLD after LT. NAFLD can also develop *de novo* post-transplantation in patients subjected to LT for other indications. Besides the pretransplant presence of various components of metabolic syndrome (MS) use of immunosuppressive agents in the post-LT setting forms one of the major drivers for the development of post-LT NAFLD. Individual components of conventional immunosuppressive regimens (corticosteroids, calcineurin inhibitors, and m-TOR inhibitors) are all implicated in the development of post-LT metabolic derangement and follow unique mechanisms of action and degree of disturbances. The development of cardiovascular risk is associated with post-LT NAFLD, although graft outcomes do not seem to be influenced only by the presence of post-LT NAFLD. Measures in consonance with the management of NAFLD, in general, including lifestyle modifications and control of metabolic risk factors, hold true for post-LT NAFLD. Tailoring immunosuppression strategies with early corticosteroid withdrawal and calcineurin inhibitor minimization balancing against the risk of graft rejection constitutes important nuances in the individualized management of post-LT NAFLD. (J CLIN EXP HEPATOL 2023;13:835–840)

Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the most common causes of chronic liver disease worldwide with an estimated global prevalence of about 30%.¹ The prevalence of NAFLD in the general population in India varies from 9 to 53% with a pooled prevalence of 39%.^{2,3} In consonance with the exponential rise, it has also established itself as one of the commonest indications of liver transplantation (LT).^{1,3} A seemingly paradoxical, but anticipated, challenge of NAFLD in the post-transplant setting has emerged synchronously with the increasing use of transplantation as well as its changing epidemiology.

NAFLD in the post-transplant setting can be classified into two subtypes, a more common recurrent NAFLD and a comparatively lesser common *de novo* NAFLD. Recurrent NAFLD is the re-occurrence of NAFLD in patients

who were originally transplanted for NAFLD-related cirrhosis or hepatocellular carcinoma (HCC).⁴ On the other hand, *de novo* NAFLD is defined as the onset of liver steatosis or non-alcoholic steatohepatitis (NASH) after at least six months of transplantation who were originally transplanted for non-NAFLD indications.⁵ While there are multiple risk factors that predispose to the development of NAFLD post-LT, in the following sections, we delve into the impact of immunosuppression on the development of NAFLD and NASH in the post-LT setting.

EPIDEMIOLOGY OF POST-LT NAFLD

Recurrent NAFLD post-LT which reflects a re-occurrence of the primary disease has been reported to be extremely common with one study reporting a prevalence of more than 90% of which 25% had advanced fibrosis.⁶ Ten-year follow-up data from a single center showed the development of NAFLD in two-thirds, with one-fourth having NASH, and 18% having significant fibrosis.⁷ Pooled meta-analysis data show an incidence of post-LT recurrent NAFLD of 59%, 57%, and 82% at 1, 3, and 5 years following LT, respectively. Similarly, the incidence of post-LT recurrent NASH has been estimated to be 53%, 57.4%, and 38% at 1, 3, and 5 years following LT, respectively.⁸ On the other hand, a recent meta-analysis of 12 studies involving 2166 patients shows that *de novo* NAFLD has a variable prevalence of 14.7%–52% post-LT which is less common than recurrent NAFLD.⁵ Furthermore, the same meta-analysis also showed a variable prevalence of 0.96%–

Keywords: liver transplantation, NASH, cryptogenic cirrhosis, metabolic syndrome, rational immunosuppression

Received: 19.2.2023; **Accepted:** 28.3.2023; **Available online** 3 April 2023

Address for correspondence: Dr Ajay Duseja, Professor and Head, Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India. Tel.: +91 172 2754791; fax: +91 0172 2744401.

E-mail: ajayduseja@yahoo.co.in

Abbreviations: CNI: Calcineurin inhibitors; CsA: Cyclosporine A; HCC: Hepatocellular carcinoma; LDL: Low-density lipoproteins; LT: Liver transplantation; MS: Metabolic syndrome; mTORi: mTOR inhibitors; NAFLD: Non-alcoholic fatty liver disease; PTMS: Post-transplant metabolic syndrome; TAC: Tacrolimus

<https://doi.org/10.1016/j.jceh.2023.03.013>

32% of biopsy-proven NASH involving eight studies in those having *de novo* NAFLD.⁵

Risk Factors for Post-transplant NAFLD

The traditional risk factors for NAFLD, including obesity, post-LT weight gain, diabetes mellitus, hypertension, and hyperlipidemia, holds true for the development of post-LT NAFLD with diabetes having a stronger association with recurrent NAFLD.^{9,10} Other risk factors that have been implicated in the development of post-LT NAFLD include age (in conjunction with components of metabolic syndrome (MS)), female gender, and genetic factors including PNPLA3 gene polymorphisms.¹¹⁻¹³ Besides, these risk factors side effects mediated by immunosuppressants have been associated with the development of post-LT NAFLD. The culminating point of all the associated risk factors is the development of post-transplant metabolic syndrome (PTMS) which, in turn, has a proportional relationship with post-LT NAFLD. In addition to the aforementioned risk factors, rapid weight gain post-LT and lower exercise intensity accelerate PTMS and post-LT NAFLD. Figure 1 provides an overview of the risk factors of post-LT NAFLD.

IMPLICATION OF INDIVIDUAL IMMUNOSUPPRESSANT DRUGS IN POST-LT NAFLD

Corticosteroids

Corticosteroids form an essential component of the immunosuppressive strategy in the immediate postoperative setting to prevent graft rejection. The use of cortico-

steroids both in the short term and long term is associated with metabolic complications and frequently leads to hyperglycemia, hypertension, hyperlipidemia, and post-transplant obesity.¹⁴ However, current day immunosuppression protocols have progressively been moving toward rapid steroid weaning protocols and steroid-free regimens which have limited the adverse effects.¹⁵ Data from protocols using steroid-free immunosuppression have shown a significantly reduced rate of new-onset diabetes post-LT.¹⁶

Calcineurin Inhibitors

The calcineurin inhibitors (CNI) [cyclosporine A (CsA) and tacrolimus (TAC)] have transformed immunosuppression practices with TAC being the current backbone of modern immunosuppression regimens. The diabetogenic mechanisms of CNIs involve multiple axes which include induction of insulin resistance, inhibition of transcription factors for beta-cell growth, downregulation of adiponectin transcription, and CNI-mediated hypomagnesemia (renal wasting) which leads to impaired insulin signaling.¹⁷ On a comparative basis, the literature from renal transplant recipients indicate toward a higher diabetogenic potential of TAC than CsA which, however, does not translate into any differences in short-term outcomes.¹⁸

Dyslipidemias are associated with both CsA and TAC with the former having a worse profile.¹⁹ The mechanisms that have been proposed for dyslipidemia include inhibition of sterol 27-hydroxylase resulting in increased 3-hydroxy-2-methylglutaryl coenzyme A activity and a subsequent increase in cholesterol levels, decrease in bile acid synthesis from cholesterol resulting in increased




Figure 1 An overview of the risk factors of post-LT NAFLD.

Table 1 Metabolic Derangements due to Individual Immunosuppressants.

Metabolic derangement	Corticosteroids	Tacrolimus	Cyclosporine	mTOR inhibitors
Mechanisms	<ul style="list-style-type: none"> ↑ Gluconeogenesis ↓ Insulin production ↑ FFA uptake ↓ Lipoprotein lipase activity 	<ul style="list-style-type: none"> ↑ Gluconeogenesis ↓ Cholesterol transport into bile ↓ Beta cell proliferation and survival ↓ Vasodilators and ↑ SVR 	<ul style="list-style-type: none"> ↑ Gluconeogenesis ↓ Cholesterol transport into bile ↓ Beta cell proliferation and survival 	<ul style="list-style-type: none"> ↓ Lipoprotein lipase activity ↑ Adipose lipase activity ↓ Beta cell proliferation
Obesity	++	–	–	–
Impaired glucose tolerance	+++	++	+	–
Dyslipidemia	++	+	++	+++
Hypertension	+	+	++	+

FFA, free fatty acid; SVR, systemic vascular resistance.

cholesterol levels, and reduction in triglyceride degradation via inhibition of lipoprotein lipase.²⁰

The development of hypertension post-transplant is common and is reported in more than 50% of the cases in some studies, and exposure to CNI has been proposed as a predominant reason for the same.^{21,22} Multiple mechanisms have been proposed including rennin and angiotensin II upregulation, decreased glomerular filtration, increased renal tubular reabsorption of sodium, sympathetic overactivity, and impairment of arterial vasodilation due to reduced levels of prostacyclin and nitric oxide.²³ Although decreased filtration and increased sodium reabsorption with renal vasoconstriction appears to be one of

the primary mechanisms, the activation of rennin-angiotensin system is not implicated as a major pathway.²²

mTOR Inhibitors (mTORi)

mTORi the newest class in the immunosuppressive armamentarium is commonly associated with the development of hyperglycemia and dyslipidemia. These tend to increase high-density lipoproteins (HDL), low-density lipoproteins (LDL), cholesterol, and triglycerides in approximately 40–75% of patients receiving therapy.²⁴ Although multiple mechanisms possibly lead to mTORi-induced dyslipidemia, the primary reasons include the inhibition of lipid transport into adipocytes and increased basal lipolysis.²⁵




Figure 2 A summary of the potential mechanisms of metabolic alterations due to various immunosuppressant drugs and individual derangements.

mTORi-induced dyslipidemia is dose-dependent as studies from renal transplant recipients have shown that with both sirolimus and everolimus lower fixed dose leads to less profound changes than higher doses, even in the presence of standard-exposure CNI therapy.^{26,27} Current day practices using low dose mTORi either in combination with CNI or in a CNI free regimen have become less intensive and with concomitant statin therapy concerns about dyslipidemia have been relatively controlled.²⁵ mTORi are also associated with hyperglycemia possibly acting through the inhibition of PI3K/AKT axis and impairment of insulin-related gene transcription.²⁴ It can be seen in up to 50% of patients with the occurrence being more frequent in those with baseline hyperglycemia.²⁸ A summary of the potential mechanisms of metabolic alterations due to various immunosuppressant drugs and individual derangements is shown in Table 1 and Figure 2.

Immunosuppression – Its Implication in Post-transplant NAFLD

As elaborated in the previous sections, the adverse metabolic impact of various classes of immunosuppressive therapies remains one of the principal concerns in the post-LT setting. Corticosteroids and CNIs are especially associated with adverse effects on the metabolic profile which become more pronounced in a background of NASH in the pre-transplant setting.⁶ While this aspect of worse metabolic profile is well established, the studies linking the effects of immunosuppressants, specifically on allograft steatosis, however, need further validation. Both tacrolimus, as well as cumulative steroid dose, have been implicated in the development of recurrent allograft NAFLD in one study.²⁹ However, another study found no association between the use of tacrolimus and post-transplant steatosis. The use of cyclosporine was found to be a predictor of post-transplant steatosis on univariate analysis in one study but did not attain statistical significance on multivariate assessment.³⁰ Therefore, although the risks of worsening metabolic profile are common with the use of immunosuppressive regimens in the post-transplant period, their impact on graft steatosis needs further substantiation.

POST-TRANSPLANT NAFLD AND IMPLICATIONS ON GRAFT SURVIVAL

In spite of post-LT NAFLD being an extremely common complication, its impact on graft survival has been variably reported. Literature from multiple studies conclude that despite a high incidence of recurrent NAFLD graft survival post-LT does not seem to be influenced by disease recurrence.^{6,7,31} Similarly, in another recent study with 275 patients with NASH who underwent LT, the authors found no difference in graft survival for patients with recurrent NASH or NAFL.³² However, it is important to emphasize

that even if the rates for long-term survival are not different, these patients remain at higher risk for cardiovascular events due to underlying metabolic disease.³⁰

MANAGEMENT OF POST-LT NAFLD: IMPLICATIONS OF IMMUNOSUPPRESSIVE STRATEGIES AND PHARMACOTHERAPY

The tenets of management of post-LT NAFLD are essentially the same as those with conventional NAFLD with stress on lifestyle modification, prevention of weight gain, dietary restriction, and achieving weight loss. The additional component involves tailoring of immunosuppression strategies to reduce the metabolic risks. The International Liver Transplantation Consensus recommends minimization of immunosuppression with an attempt for early steroid withdrawal. Additional, strategies include switching from tacrolimus to cyclosporine in cases of uncontrolled hyperglycemia or from cyclosporine to tacrolimus in cases of dyslipidemia.³³ In similar lines, for patients with recurrent NASH, the Indian National Society for the study of the liver recommends early steroid taper and advocates mycophenolate mofetil as the drug with the least metabolic complications in such settings.³⁴ However, the most important consideration that remains to be kept in the backdrop is the optimization of graft and patient survival. An approach to control metabolic derangements and rational immunosuppression is shown in Table 2. Literature regarding specific NAFLD-directed therapy in the post-LT setting is limited. None of the drugs

Table 2 Approaches to Control of Metabolic Derangements and Rational Immunosuppression.

Metabolic parameters	Management options	Rational immunosuppression
Low-density lipoprotein >100 mg/dL Higher triglycerides	<ul style="list-style-type: none"> Lifestyle modification Diet changes Statins/ezetimibe if not controlled by diet and lifestyle Fibric acid derivatives, fish oils 	<ul style="list-style-type: none"> CNI reduction and addition of mycophenolate Cyclosporine conversion to tacrolimus
Diabetes mellitus	<ul style="list-style-type: none"> Target HbA1c < 7% Lifestyle changes Oral antidiabetics Insulin may be preferred when on high doses of steroids 	<ul style="list-style-type: none"> Steroid short-term only Steroid-free protocols Tacrolimus to cyclosporine
Hypertension	<ul style="list-style-type: none"> Blood pressure 130/80 mm Hg Calcium channel blockers: amlodipine/nifedipine may be the preferred drug of choice 	Steroid and CNI minimization

CNI, calcineurin inhibitors.

which have been used in the pre-LT setting have robust data in post-LT NAFLD and hence are not recommended as of now. Saroglitazar, a dual peroxisome proliferator-activated receptor- α/γ agonist which has shown promising results in the pre-LT setting with regulatory approval in India, is currently being evaluated for patients with post-LT NAFLD (NCT03639623).³⁵

NAFLD post-LT is common and is influenced by baseline metabolic profile, post-transplant weight gain, poor metabolic control, and adverse effects of immunosuppressants. The impact of immunosuppression on individual metabolic derangements has been clearly delineated; however, its composite impact on post-LT NAFLD remains to be determined. Although overall graft and patient survival may not be affected with the development of post-LT NAFLD *per se*, cardiovascular outcomes are worse on account of poor metabolic profile. Strict regulation of metabolic risk factors, lifestyle interventions, and targeted pharmacotherapy toward medical management of metabolic complications and rational immunosuppression form the core strategies for the control and management of post-LT NAFLD.

CREDIT AUTHORSHIP CONTRIBUTION STATEMENT

Ajay Duseja: conceptualization, methodology, software
Akash Roy: data curation, writing-original draft preparation.
Sunil Taneja: visualization, investigation. **Sunil Taneja:** supervision. **Akash Roy:** software, validation. **Ajay Duseja/Sunil Taneja:** writing-reviewing and editing.

CONFLICTS OF INTEREST

The authors have none to declare.

FUNDING

Nil.

REFERENCES

1. Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review. *Hepatology*. 2023;10–97.
2. Elhence A, Bansal B, Gupta H, Anand A, Singh TP, Goel A. Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis. *J Clin Exp Hepatol*. 2021 <https://doi.org/10.1016/j.jceh.2021.11.010>.
3. De A, Duseja A. Nonalcoholic fatty liver disease: Indian perspective. *Clin Liver Dis*. 2021;158–163.
4. Patil DT, Yerian LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. *Liver Transpl*. 2012;18:1147–1153.
5. Losurdo G, Castellana A, Rendina M, et al. Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. *Aliment Pharmacol Ther*. 2018;47:704–714.
6. Bhati C, Idowu MO, Sanyal AJ, et al. Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis. *Transplantation*. 2017;101:1867–1874.
7. Malik SM, deVera ME, Fontes P, et al. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. *Liver Transpl*. 2009;15:1843–1851.
8. Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis. *Transplantation*. 2019 Nov 1;103:e345–e354.
9. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. *Am J Transplant*. 2004;4:686–693.
10. Vallin M, Guillaud O, Boillot O, et al. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis. *Liver Transpl*. 2014;20:1064–1071.
11. Collins BH, Pirsch JD, Becker YT, et al. Long-term results of liver transplantation in older patients 60 years of age and older. *Transplantation*. 2000;70:780–783.
12. Kappus M, Abdelmalek M. De novo and recurrence of nonalcoholic steatohepatitis after liver transplantation. *Clin Liver Dis*. 2017;21:321–335.
13. Finkenstedt A, Auer C, Glodny B, et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. *Clin Gastroenterol Hepatol*. 2013;11:1667–1672.
14. Lane JT, Dagogo-Jack S. Approach to the patient with new-onset diabetes after transplant (NODAT). *J Clin Endocrinol Metab*. 2011 Nov 1;96:3289–3297.
15. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation 1. *Clin Transplant*. 2005 Jun;19:291–298.
16. Castedal M, Skoglund C, Axelson C, Bennet W. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation. *Scand J Gastroenterol*. 2018 Jun 3;53:741–747.
17. Van Laecke S, Desideri F, Geerts A, et al. Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. *Liver Transpl*. 2010 Nov;16:1278–1287.
18. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. *Am J Transplant*. 2007 Jun;7:1506–1514.
19. Sarumathy S, George P, Kumar B, Mukundan VA, Shanmugarajan TS, Maheshwari P. Clinical comparison of serum lipids between cyclosporine and tacrolimus treated renal transplant recipients. *Res J Pharm Technol*. 2016;9:694–698.
20. Tory R, Sachs-Barrable K, Goshko CB, Hill JS, Wasan KM. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. *Transplantation*. 2009 Jul 15;88:62–68.
21. Canzanello VJ, Schwartz L, Taler SJ, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). *Liver Transpl Surg*. 1997 Jan;3:1–9.
22. Hryniewiecka E, Żegarska J, Paczek L. Arterial hypertension in liver transplant recipients. In: *Transplantation proceedings*. 2011 <https://doi.org/10.1016/j.transproceed.2011.07.011>.
23. Canzanello VJ, Textor SC, Taler SJ, et al. Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation. *J Am Soc Nephrol*. 1995 May 1;5:1910–1917.

24. Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. *Expert Opin Drug Saf.* 2013 Mar 1;12:177–186.
25. Holdaas H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? *Transplant Rev.* 2015 Apr 1;29:93–102.
26. Vitko S, Wlodarczyk Z, Kyllönen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. *Am J Transplant.* 2006 Mar;6:531–538.
27. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. *Am J Transplant.* 2004 Apr;4:626–635.
28. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. *J Am Soc Nephrol.* 2008 Jul 1;19:1411–1418.
29. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. *Liver Transpl.* 2001;7:363–373.
30. Yalamanchili K, Saadeh S, Klintmalm GB, et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. *Liver Transpl.* 2010;16:431–439.
31. Narayanan P, Mara K, Izzy M, et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation. *Transplantation.* 2019 Jan 1;103:e14–e21.
32. Matsuoka L, Chotai PN, Slaughter J, et al. A single-center study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis recurrence in recipients of liver transplant for treatment of nonalcoholic steatohepatitis cirrhosis. *Exp Clin Transplant.* 2022 Feb <https://doi.org/10.6002/ect.2021.0343>.
33. Charlton M, Levitsky J, Aql B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. *Transplantation.* 2018 May 1;102:727–743.
34. Duseja A, Singh SP, De A, et al. Indian National Association for Study of the Liver (INASL) guidance paper on nomenclature, diagnosis and treatment of non-alcoholic fatty liver disease (NAFLD). *J Clin Exp Hepatol.* 2022 <https://doi.org/10.1016/j.jceh.2022.11.014>.
35. Gawrieh S, Nouredin M, Loo N, et al. Saroglitazar, a PPAR- α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. *Hepatology.* 2021;74:1809–1824.